Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)

2.75
Delayed Data
As of Sep 23
 +0.10 / +3.77%
Today’s Change
1.23
Today|||52-Week Range
16.97
-72.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$81.2M

Company Description

Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It is engaged in the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases. The company's lead product, lomitapide, is a small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. The company was founded by David I. Scheer and William H. Lewis on February 4, 2005 and is headquartered in Cambridge, MA.

Contact Information

Aegerion Pharmaceuticals, Inc.
One Main Street
Cambridge Massachusetts 02142
P:(617) 500-7867
Investor Relations:
(857) 242-5024

Employees

Shareholders

Other institutional71.20%
Individual stakeholders51.99%
Mutual fund holders17.89%

Top Executives

Mary J. SzelaChief Executive Officer & Director
Gregory D. PerryChief Financial & Administrative Officer
Barbara Y. ChanChief Accounting Officer & Vice President
William AndrewsSenior Vice President-Business Development
Carolina AlarcoPresident-International